Octreotide Teva (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotide Teva, is a peptide presented as a sterile solution for subcutaneous injection use. It treats symptoms associated with hormone‑secreting tumors and related gastrointestinal disorders in adults.

GNH USA supplies Octreotide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Octreotide Teva is a somatostatin analogue that modulates neuro‑endocrine activity in several disease pathways. - Acromegaly: reduces excessive growth hormone secretion and helps control serum IGF‑1 levels. - Carcinoid syndrome: lessens flushing and diarrhoea associated with serotonin‑rich tumors. - VIPoma/Medullary thyroid carcinoma: controls severe diarrhoea and flushing. - Bleeding variceal prophylaxis: lowers portal‑portal pressure, aiding in the prevention of upper gastro‑intestinal bleeding. - Diagnostic imaging: enhances the detection of somatostatin‑receptor positive tumours. - Symptomatic treatment of neuro‑endocrine tumours with functional hormone secretion of the gster ​

Oct8  g